SCMP Sucampo Pharmaceuticals, Inc. (delisted)

Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in a fireside chat at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27th at 3:30PM Eastern.

Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.

The fireside chat will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. 

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA. For more information, please visit www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).Twitter   LinkedIn

Contact:Sucampo Pharmaceuticals, Inc.Silvia TaylorSenior Vice President, Investor Relations and Corporate Affairs1-240-223-3718staylor@sucampo.com